TCI Wealth Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

TCI Wealth Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,340	Closed	-$5K	–	2620
2022 Q1	$5K	Buy	+2,340	New	+$4.6K	﹤0.01%	1641

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

TCI Wealth Advisors's CLVS Position: Q2 2022 in Review

TCI Wealth Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 2,340 shares — an estimated $5K sold.

TCI Wealth Advisors first reported a position in CLVS in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

TCI Wealth Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
TCI Wealth Advisors sold 2,340 Clovis Oncology, Inc. shares in Q2 2022, an estimated $5K.
TCI Wealth Advisors first reported a position in Clovis Oncology, Inc. in Q1 2022 and held it in 1 quarter.
TCI Wealth Advisors's Clovis Oncology, Inc. position peaked at $5K in Q1 2022.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on TCI Wealth Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.